Create Medicines secured a $122 million Series B financing round.
The round was led by Newpath Partners, ARCH Venture Partners, Hatteras Venture Partners, Alexandria Venture Investments, and others.
The company is using the capital to advance its early pipeline in autoimmune disease and cancer.
Create says its autoimmune programs are still entirely preclinical.
Its cancer portfolio has already dosed more than 50 patients, which it describes as the largest clinical dataset in the field.
The funds will support development of lead candidate GT801, a phase 1 therapy for relapsed or refractory CD19-positive B-cell malignancies.
Create reported first-in-human data for GT801 at the ASH annual meeting last December.
The new financing will also support planned regulatory submission and expansion of the company’s research team and platform.